MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100677-PIP01-22-M01) and to the deferral

MHRA-100677-PIP01-22-M02

Scope of the Application

Active Substance(s)

COBICISTAT

Condition(s)

Treatment of human immunodeficiency virus type-1 (HIV-1) infection

Pharmaceutical Form(s)

Film-coated tablet Age-appropriate tablet Age-appropriate dispersible tablet

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Gilead Sciences Ltd

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Gilead Sciences Ltd submitted to the licensing authority on 15/05/2025 22:22 BST an application for a Modification

The procedure started on 10/06/2025 14:25 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100677-PIP01-22-M02

Of 02/09/2025 12:00 BST

On the adopted decision for COBICISTAT (MHRA-100677-PIP01-22-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for COBICISTAT, Film-coated tablet Age-appropriate tablet Age-appropriate dispersible tablet , ORAL USE .

This decision is addressed to Gilead Sciences Ltd, 280 High Holborn, London, UNITED KINGDOM, WC1V 7EE

ANNEX I

1. Waiver

1.1 Condition:

Treatment of human immunodeficiency virus type-1 (HIV-1) infection The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 3 months of age Pharmaceutical form(s): Film-coated tablet Age-appropriate tablet Age-appropriate dispersible tablet Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of human immunodeficiency virus type-1 (HIV-1) infection

2.2 Indication(s) targeted by the PIP:

Treatment of human immunodeficiency virus type-1 (HIV-1) infection in paediatric patients - pharmacokinetic enhancer of atazanavir or darunavir for use in combination with antiretroviral agents

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 3 months to less than 18 years of age

2.4 Pharmaceutical Form(s):

Film-coated tablet Age-appropriate tablet Age-appropriate dispersible tablet

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	2	Study 1 Development of an age-appropriate tablet. Study 2 Development of an age-appropriate dispersible tablet.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 3 (GS-US-216-0127) Open-label, randomised crossover trial in healthy adult subjects to determine the relative bioavailability of the adult cobicistat film coated tablet to an age-appropriate tablet (Cohort 1) and to an age-appropriate dispersible tablet (Cohort 2). Study 4 (GS-US-216-0128) (Same study as Study 9 of the emtricitabine/tenofovir alafenamide PIP MHRA-100676-PIP01-22-M01 and subsequent modifications thereof. No patients below 3 months of age are required to be treated with cobicistat, only the older ones. The younger cohorts will use other components of the FDC.) Open-label trial to evaluate pharmacokinetics (PK), safety, and efficacy of cobicistat-boosted protease inhibitors and once daily emtricitabine/tenofovir alafenamide each administered as part of combined ARV regiment

		in HIV-1 infected children from 4 weeks to less than 18 years of age.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/01/2026
Deferral of one or more studies contained in the paediatric investigation plan:	Yes